Categories Other Industries

Pfizer’s cancer drug hits FDA roadblock

With the loss of patent protection for its flagship drugs – Lipitor and Viagra – drugmaker Pfizer (PFE) has been struggling to revive its sales. The pharma giant has been investing heavily in biosimilars and has been on a look for new growth avenues, but it is not immune to setbacks. The company hit a roadblock after the US Food and Drug Administration turned away the company’s biosimilar version of Herceptin – Roche’s blockbuster cancer drug.

 

Image courtesy : Norbert Nagel, Wikimedia Commons

According to the estimates provided by Forbes last year, Roche’s oncology business – with key drugs namely Avastin, Herceptin, and Rituxan – generates nearly 50% of the total revenue. A cheaper version of these drugs is expected to take a bite out of the company’s cancer sales in 2020.

Roche – the Swiss drugmaker – is under pressure as Herceptin is near to losing its patent protection. The fear of intensifying competition forced Roche to sue Pfizer last year to block the latter’s biosimilar version of Herceptin. The lawsuit filed by Roche claims that Pfizer would violate nearly 40 of its patents with a biosimilar version of the breast cancer treatment.

The company hit a roadblock after the US Food and Drug Administration turned away the company’s biosimilar version of Herceptin – Roche’s blockbuster cancer drug.

But now that the FDA has issued Complete Response Letter (CRL) seeking additional technical information, Roche probably breathed a sigh of relief. Pfizer conciliated its investors stating the FDA did not seek information on safety and clinical data.

If Pfizer wins the FDA approval, it will have to compete against Mylan (MYL). Last year Mylan along with Biocon, its partner, got an OKAY from the FDA for a biosimilar version of Herceptin – Ogivri.

Pfizer has in the past encountered several challenges over biosimilars. The company’s attempt at producing a biosimilar version of Epogen – Amgen’s (AMGN) anemia drug – was flatly rejected by the FDA. The latest FDA rejection, however, coincided with Pfizer winning the approval from the FDA for a breakthrough therapy status for MenB vaccine in children.

Most Popular

AVGO Earnings: All you need to know about Broadcom Q1 2021 earnings results

Broadcom Limited (NASDAQ: AVGO) reported first quarter 2021 earnings results today. Total revenue increased 14% year-over-year to $6.65 billion. GAAP net income was $1.3 billion, or $3.05 per share, compared

Infographic: Costco (COST) Q2 2021 sales up 15%; earnings miss

Retail giant Costco Wholesale Corporation (NASDAQ: COST) reported higher earnings and revenues for the second quarter of 2021. Earnings missed analysts’ expectations, while sales beat. Net profit was $951 million

Will shifting to as-a-service model help Hewlett Packard in emerging stronger from COVID?

With the corporate world rapidly shifting to cloud-native computing after the virus outbreak changed work culture and the way businesses operate, technology providers are aggressively innovating their offerings. Hewlett Packard

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top